Medical Predictive Science Corporation



Home	About MPSC	HeRO™	News	References	Links	Contact Us
HeRO™ Patient Outcomes Study Receives NIH Grant July 1, 2005 - Charlottesville, VA. Medical Predictive Science Corporation has announced that the University of Virginia (UVA) has been granted $2 million by the National Institutes of Health (NIH) to oversee a multi-center clinical trial to investigate the effects of the Heart Rate Observation (HeRO™) system on patient outcomes in the Neonatal Intensive Care Unit (NICU). Dr. J. Randall Moorman, of the UVA Department of Cardiology, will be the Principal Investigator for the study. The HeRO™ system analyzes the beat-to-beat heart rate of neonatal patients to detect abnormal patterns such as transient decelerations and reduced baseline variability. Once per hour, it generates a score for each patient that indicates the degree of abnormality. This score has been correlated to significant clinical markers, indicating that it may have value in predicting the onset of infection. The clinical trial will examine the effects of making the HeRO™ score available to caregivers by randomly assigning patients at study sites to two groups. The scores will be shown for patients that are randomized into the Study group, allowing physicians to take this information into account when deciding the course of treatment. For patients randomized into the Control group, the scores will be hidden. The overall effect of the HeRO™ system will then be determined by tracking patient outcome measures such as length of stay, days on mechanical ventilation, blood culture orders, and antibiotic usage. Additional secondary measures, such as mortality, will also be monitored. "We feel there is no more important problem in clinical neonatology," said Dr. Moorman. He added, "this approach represents a truly novel method to assist clinical neonatologist in early diagnosis of sepsis." Dr. Moorman is a co-inventor of the heart rate characteristics algorithms used in the HeRO™ system, along with Dr. M. Pamela Griffin, a neonatologist formerly with UVA. # # # Medical Predictive Science Corporation (http://www.mpsc.biz) is engaged in the development of computational diagnostic and bio-informatic technologies for the healthcare industry. MPSC is committed to saving lives and reducing healthcare expenditures through the development of effective clinical diagnostic and decision support tools. These products use computational diagnostic methods to make the early diagnosis of clinical illness through continuous, non-invasive patient monitoring, and to provide diagnostic information as well as decision support to the physician. HeRO is a trademark of Medical Predictive Science Corporation.


About MPSC \| HeRO™ Product Information \| References Cite HeRO™ \| Contact Us \| Legal \| News \| Support \| Home © 2006. HeRO is a trademark of Medical Predictive Science Corporation.